News

Obtaining the drug certificate is in continuation of Sinovac’s strategy to explore opportunities to export its vaccines manufactured in mainland China to targeted areas and countries worldwide. Sinovac

Based on the first contract with the Beijing CDC, Sinovac is expected to supply 375,000 doses of seasonal influenza vaccine, Anflu, valued at $1.3m. Sinovac chairman, president and

Fipamezole is being prepared for Phase III development for the treatment of Dyskinesia in Parkinson’s Disease. Previously, Santhera has entered into a collaboration and licensing agreement with Biovail

Menveo showed immunogenicity in infants potentially offering protection against four major serogroups of meningococcal disease. Menveo was generally well tolerated when given either alone or co-administered with other

Dr Reddy’s Laboratories has posted a net income of $64m for the Q2 FY11, or $0.4 per diluted share, compared to net income of $48.92m, or $0.3 per

NeuroVive will fund the initial development up to preclinical Proof of Concept, after which the two companies have agreed to develop and commercialize the product jointly. to-BBB CSO

The Phase III randomised, blinded, controlled study was conducted at trial sites in Germany and Finland. Novartis said that the study aimed to assess the reactogenicity of the

Under the agreement, GSK will retain the existing rights for these products in countries outside the US, except for Daraprim in Canada, where rights will also be divested

AstraZeneca said that the CHMP issued its opinion for marketing Fluenz Influenza vaccine in Europe for children 24 months to less than 18 years of age. AstraZeneca’s Fluenz